L6785
Lactacystin
≥90% (HPLC), powder, proteosome inhibitor
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C15H24N2O7S
CAS Number:
Molecular Weight:
376.43
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Lactacystin, ≥90% (HPLC)
Quality Level
assay
≥90% (HPLC)
form
powder
potency
4 nM Ki (proteasome inhibitor)
solubility
water: 10 mg/mL, clear, colorless
storage temp.
−20°C
SMILES string
CC(C)[C@H](O)[C@]1(NC(=O)[C@H](C)[C@@H]1O)C(=O)SC[C@H](NC(C)=O)C(O)=O
InChI
1S/C15H24N2O7S/c1-6(2)10(19)15(11(20)7(3)12(21)17-15)14(24)25-5-9(13(22)23)16-8(4)18/h6-7,9-11,19-20H,5H2,1-4H3,(H,16,18)(H,17,21)(H,22,23)/t7-,9+,10+,11+,15-/m1/s1
InChI key
DAQAKHDKYAWHCG-RWTHQLGUSA-N
General description
Lactacystin is an antibiotic and a metabolite of Streptomyces spp.
Application
Lactacystin has been used:
- as a proteasome inhibitor to inhibit protein degradation
- to inhibit proteasomal activity of cells for live cell imaging
- to block proteasomal proteolysis in human monocyte-derived dendritic cells (MoDCs) for 24 h
- to provide unilateral injection to animals to induce nigrostriatal lesions
Biochem/physiol Actions
Lactacystin can block the development of cell cycle and stimulate differentiation in a murine neuroblastoma cell line. It can serve as a precursor for clasto-lactacystin β-lactone. Cell-permeable and irreversible proteasome inhibitor (Ki = 4nM). Inhibits NF-kB activation (IC50 = 10mM). Induces neurite outgrowth in neuro2A mouse neuroblastoma cells.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin A CENTRAL ROLE FOR clasto-LACTACYSTIN beta-LACTONE
Dick L R, et al.
The Journal of Biological Chemistry, 271(13), 7273-7276 (1996)
Differential regulation of MHC II and invariant chain expression during maturation of monocyte-derived dendritic cells
Landsverk O J B, et al.
Journal of Leukocyte Biology, 91(5), 729-737 (2012)
Dallas S Shi et al.
The Journal of clinical investigation, 124(9), 3757-3766 (2014-07-26)
The proteasome inhibiter bortezomib has been successfully used to treat patients with relapsed multiple myeloma; however, many of these patients become thrombocytopenic, and it is not clear how the proteasome influences platelet production. Here we determined that pharmacologic inhibition of